SCHEMBL3637097

SCHEMBL3637097

O=c1c(OS(=O)(=O)[O-])c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12.[H+]

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 7/20 0.71
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
KDM4E B2RXH2 4/20 0.71
POLB P06746 3/20 0.71
GAA P10253 3/20 0.71
RECQL P46063 3/20 0.71
HSD17B10 Q99714 3/20 0.71
MMP1 P03956 2/20 0.71
MAPT P10636 2/20 0.71
APEX1 P27695 2/20 0.71
BLM P54132 2/20 0.71
HTT P42858 1/20 0.71
EPHX2 P34913 4/20 0.64
SLCO2B1 O94956 3/20 0.64
AKR1B1 P15121 3/20 0.64
MAOA P21397 3/20 0.64
XDH P47989 3/20 0.64
USP2 O75604 2/20 0.64
TP53 P04637 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL4649852 0.98 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL10861623 0.91 POLH (0.78) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL29897597 0.89 POLH (0.72) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL3403244 0.89 POLH (0.72) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL3735023 0.89 MEN1 (0.68) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL3727376 0.88 TUBB4A (0.78) POLHMEN1KMT2AKDM4EPOLB
Potassium Ion SCHEMBL29466606 0.87 MEN1 (0.68) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL3642775 0.87 TUBB4A (0.70) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL14786208 0.85 POLH (0.81) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL28297226 0.84 POLH (0.79) POLHMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279961-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE ANALYTICON DISCOVERY GMBH (DE) 2010-11-04 US claimed
EP-2164477-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE Analyticon Discovery GmbH (DE) 2010-03-24 EP claimed
WO-2008154900-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE ANALYTICON DISCOVERY GMBH (DE) 2008-12-24 WO claimed
US-20100279961-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE ANALYTICON DISCOVERY GMBH (DE) 2010-11-04 US disclosed
EP-2164477-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE Analyticon Discovery GmbH (DE) 2010-03-24 EP disclosed
WO-2008154900-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE ANALYTICON DISCOVERY GMBH (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279961-A1 PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE UGT2B17, UGT1A3, UGT1A4 POLH 3433/4885MEN1 2912/4885KMT2A 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.